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Abstract
Background: Follow-up epidemiologic studies are needed to assess trends and patterns of disease spread. No
follow-up epidemiologic study has been done in the Kingdom of Saudi Arabia to assess the current prevalence of
major chronic, noncommunicable diseases, specifically in the urban region, where modifiable risk factors remain
rampant. This study aims to fill this gap.
Methods: A total of 9,149 adult Saudis ages seven to eighty years (5,357 males (58.6%) and 3,792 females (41.4%))
were randomly selected from the Riyadh Cohort Study for inclusion. Diagnosis of type 2 diabetes mellitus (DMT2)
and obesity were based on the World Health Organization definitions. Diagnoses of hypertension and coronary
artery disease (CAD) were based on the Seventh Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure and American Heart Association criteria, respectively.
Results: The overall crude prevalence of DMT2 was 23.1% (95% confidence interval (95% CI) 20.47 to 22.15). The age-
adjusted prevalence of DMT2 was 31.6%. DMT2 prevalence was significantly higher in males, with an overall age-
adjusted prevalence of 34.7% (95% CI 32.6 to 35.4), than in females, who had an overall age-adjusted prevalence of
28.6% (95% CI 26.7 to 29.3) (P < 0.001). The overall crude prevalence of obesity was 31.1% (95% CI 30.1 to 32.0). The
age-adjusted prevalence of obesity was 40.0%. The prevalence of obesity was higher in females, with an overall
prevalence of 36.5% (95% CI 35.1 to 37.83), than in males (25.1% (95% CI 23.7 to 26.3)) (P < 0.001). The age-adjusted
prevalence of hypertension and CAD were 32.6% (95% CI 31.7 to 33.6) and 6.9% (95% CI 6.4 to 7.4), respectively.
Conclusion: Comparisons of our findings with earlier data show that the prevalence of DMT2, hypertension and
CAD in Riyadh, Saudi Arabia, has alarmingly worsened. Aggressive promotion of public awareness, continued
screening and early intervention are pivotal to boosting a positive response.
Background
If the prevalence of diabetes mellitus type 2 (DMT2)
continues to increase at the current rate, the global bur-
den of this disease will swell between 2000 to 2030 from
171 million to 366 million patients [1]. Furthermore,
healthcare expenditures on DMT2 alone will skyrocket
from US$376 billion in 2010 to US$490 billion in 2030
[2]. The Middle East region has not been spared from
this scourge and currently is among those worst-hit [1].
This global epidemic, shared by both industrialized and
developing countries, has stimulated increased public
awareness of the disease, the identification of risk factors
and the knowledge that DMT2 can be delayed and, even
better, prevented [3-5]. Recognition of the importance
of glycemic control in the prevention of the complica-
tions and morbidity of DMT2 has led to worldwide
campaigns for modifications in lifestyle and an intensive
search for better antidiabetes medications [6-8].
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prevalence of DMT2 started to gain attention years after
rapid industrialization took place in the country [9]. Stu-
dies done since the late 1980s have shown an increasing
trend among adult Saudis [10-12], the last of which,
conducted in a large cohort of patients assembled from
1995 to 2000, revealed that one of five adult Saudis had
DMT2 [13]. The same cohort showed an alarming pre-
valence of obesity at 40.0%, hypertension at 30% and
coronary artery disease (CAD) at 6.2% [14-16]. A decade
passed, and a follow-up epidemiologic study was
designed to assess the current status of the population
and whether the efforts of the Ministry of Health and
the healthcare community have borne fruit.
Methods
The patients were part of the capital-wide Biomarker
Screening in Riyadh (BSR), an ongoing collaborative effort
between the Biomarkers Research Program (BRP) of King
Saud University and the Ministry of Health in Riyadh,
KSA (RIYADH Cohort). In brief, BSR was launched to
identify and employ novel biomarkers of chronic noncom-
municable diseases, including diabetes mellitus (DM), car-
diovascular diseases, hypertension and obesity, among
consenting Saudis. Ethical approval was obtained from the
Ethics Committee of the College of Science Research Cen-
ter of King Saud University, Riyadh, KSA.
Patients’ information was taken from the existing
database of more than 17,000 individuals. In this cross-
sectional, observational study, a total of 9,149 Saudis
(5,357 males (58.6%) and 3,792 females (41.4%)) ages
seven to eighty years old were included. Patients were
recruited randomly from their homes using the cluster
sampling strategy. They were invited to visit the nearest
primary healthcare center (PHCC). These centers span
the entire Riyadh region. The population of each PHCC
was taken as a cluster, and the allocations of the
required numbers of patients were proportional to the
populations served by the PHCCs. No expatriates were
included in the conduct of this study. Each participating
patient filled in a general questionnaire containing
demographic, past and present medical history, as well
as diet information from the food frequency question-
naire. This questionnaire was developed, pretested and
validated in a pilot study. Informed written consent was
obtained from each patient prior to inclusion.
Anthropometrics
A n t h r o p o m e t r yi n c l u d e dh e i g h t( r o u n d e do f ft ot h e
nearest 0.5 cm) and weight (rounded off to the nearest
0.1 kg), which were measured using an appropriate
international standard scale (Digital Person Scale;
ADAM Equipment, Milford, CT, USA), as well as waist
and hip circumference in centimeters, which were
measured using a standard tape measure. Mean systolic
and diastolic blood pressure readings (in mmHg; average
of two readings) were taken using appropriate cuffs.
Biochemical measurements
Consenting adults were invited to their respective PHCCs
after a 10-hour overnight fast. Blood was drawn, centri-
fuged and processed on the same day. Both whole blood
and serum were placed in plain polystyrene tubes. Serum
was delivered to BRP for storage at -20°C. Fasting serum
glucose was quantified using routine laboratory analysis
(Konelab, Espoo, Finland). This biochemical analyzer was
calibrated routinely prior to the analysis of all serum
samples using quality control samples provided by the
manufacturer (ThermoFisher Scientific, Espoo, Finland).
The glucose-measuring method employed a glucose
oxidase and modified Trinder color reaction catalyzed by
the enzyme peroxidase.
Diagnosis of chronic noncommunicable diseases
The World Health Organization (WHO)-proposed cut-
offs for DMT2 and impaired fasting glucose (IFG) were
used. DMT2 was associated with a fasting plasma glucose
(FPG) level ≥7.0 mmol/L (126 mg/dL), IFG with FPG
level between 6.1 and 6.9 mmol/L (110 to 125 mg/dL)
and normal with a FPG level < 6.1 mmol/L (110 mg/dL).
All patients whose glucose levels exceeded the cutoffs
were referred back to their respective PHCC physician
for further tests and classification of DM. Screening for
adult hypertension was based on the recommendations
of the Seventh Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood
Pressure [17]. Body Mass Index (BMI) was calculated as
body weight in kilograms divided by height in square
meters. Overweight was defined as a BMI of 25 to 29.9
kg/m
2, and obesity was defined as a BMI ≥30. For
patients ages 7 to 17 years, the cutoffs proposed by Cole
and colleagues [18] were used for the definition of over-
weight and obesity. Diagnosis of hypertension in children
was based on percentile [19]. CAD patients were known
cases based on a medical history of angiography and
intake of antiarrhythmic drugs.
Data analysis
Statistical analyses were carried out using SPSS 16.0 for
Windows software (SPSS Inc., Chicago, IL, USA). The
prevalence data for each of the various patient groups
are shown with 95% confidence intervals. Prevalence
was also calculated for gender and various age strata.
Results
The overall crude prevalence of DMT2 was 23.1% (95%
confidence interval (95% CI) 20.47 to 22.15). The age-
adjusted prevalence of DMT2 was 31.6%. The overall
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8.37 to 9.53), with an age-adjusted prevalence of 10.2%.
The prevalence of DMT2 was significantly higher in
males, with an overall age-adjusted prevalence of 34.7%
(95% CI 32.6 to 35.4), than in females (28.6% (95% CI
26.7 to 29.3)) (P < 0.001). The overall crude prevalence of
obesity was 31.1% (95% CI 30.1 to 32.0). The age-
adjusted prevalence of obesity was 40.0%. The overall
prevalence of overweight, on the other hand, was 26.3%
(95% CI 25.3 to 27.2), with an age-adjusted prevalence of
30.8%. The prevalence of obesity was significantly higher
in females, with an overall prevalence of 36.5% (95% CI
35.1 to 37.83), than in males (25.1% (95% CI 23.7 to
26.3)) (P < 0.001). The overall prevalence of CAD was
4.2% (95% CI 3.9 to 4.7), with an age-adjusted prevalence
of 6.9% (95% CI 6.4 to 7.4). The overall prevalence of
hypertension was 25.7% (95% CI 24.8 to 26.6), with an
age-adjusted prevalence of 32.6% (95% CI 31.7 to 33.6).
Tables 1 and 2 show the overall prevalence of DMT2
and the rest of the nonchronic diseases, as well as the
gender-stratified prevalence according to age. Figure 1
shows the increasing trend of DMT2 from 1997 to
2011, as well as data for other chronic noncommunic-
able diseases in comparison to previous estimates.
Table 1 Prevalence of chronic noncommunicable diseases according to age group
a
Age
group, yr
Patients,
n
DMT1 DMT2 GDM IGT Overweight Obese HPN CHD
7 to 17 2,519 0.4
(0.15 to 0.65)
4.5
(3.72 to 5.34)
5.6
(4.7 to 6.5)
16.6
(15.18 to
18.08)
12.54
(11.25 to
13.8)
18 to 45 3,954 1.3
(0.94 to 1.64)
12.2
(11.14 to
13.18)
1.39
(1.03 to 1.75)
9.6
(8.64 to
10.48)
27.9
(26.5 to
29.35)
33.4
(31.9 to 34.8)
14.0
(12.9 to 15.1)
1.5
(1.2 to 1.9)
46 to 60 1,758 3.13
(2.32 to 3.94)
46.7
(44.37 to
49.03)
1.5
(0.92 to 2.04)
12.1
(10.54 to
13.58)
31.8
(29.6 to 33.9)
50.5
(48.2 to 52.8)
40.7
(38.4 to 43.0)
10.4
(8.9 to 11.8)
61 to 80 918 4.79
(3.41 to 6.17)
58.2
(54.9 to 61.4)
9.6
(7.7 to 11.5)
35.1
(31.9 to 38.2)
34.5
(31.4 to 37.6)
58.2
(55.0 to 61.4)
14.5
(12.3 to 16.8)
aDMT1, type 1 diabetes mellitus; DMT2, type 2 diabetes mellitus; GDM, gestational diabetes mellitus; IGT, impaired glucose tolerance; HPN, hypertension; CHD,
coronary heart disease. Data are presented as percentages (95% confidence interval).
Table 2 Prevalence of chronic noncommunicable diseases according to gender
a
Gender Age group,
yr
Patients,
n
DMT1 DMT2 GDM IGT Overweight Obese HPN CHD
Men 7 to 17 1,376 0.4
(0.1 to
0.8)
4.6
(3.5 to 5.7)
5.6
(4.4 to 6.8)
15.2
(13.3 to
17.1)
12.0
(10.3 to
13.7)
1.3 (0.71 to 1.9) 0
18 to 45 1,581 1.83
(1.2 to
2.5)
15.8
(14.0 to
17.5)
10.9
(9.4 to
12.4)
29.4
(27.2 to
31.7)
28.8
(26.6 to
31.1)
16.8 (14.9 to
18.6)
2.3 (1.6 to 3.1)
46 to 60 823 2.94
(1.8 to
4.1)
49.9
(46.5 to
53.4)
9.9
(7.8 to
11.9)
39.0
(35.7 to
42.4)
37.6
(34.3 to
40.9)
41.6 (38.2 to
45.0)
11.2 (9.1 to
13.4)
61 to 80 586 4.1
(2.5 to
5.7)
61.0
(57.0 to
64.9)
7.9
(5.7 to
10.1)
37.6
(33.7 to
41.6)
27.8
(24.2 to
31.4)
57.2 (53.2 to
61.2)
16.2 (13.1 to
19.2)
Women 7 to 17 1,143 0.4
(0.1 to
1.0)
4.3
(3.1 to 5.5)
5.5
(4.2 to 6.9)
18.5
(16.3 to
20.8)
12.9
(10.9 to
14.8)
1.4 (0.72 to 2.1) 0
18 to 45 2,373 0.9
(0.6 to
1.3)
9.6
(8.4 to
10.8)
1.39
(1.03 to
1.75)
8.6
(7.5 to 9.8)
26.9
(25.1 to
28.7)
36.4
(34.5 to
38.4)
12.2 (10.8 to
13.5)
1.03 (0.62 to
1.4)
46 to 60 935 3.23
(2.1 to
4.4)
44.1
(40.8 to
47.3)
1.5
(0.92 to
2.04)
13.9
(11.6 to
16.1)
25.4
(22.6 to
28.2)
61.9
(58.7 to
64.9)
39.9 (36.7 to
43.0)
9.7 (7.8 to 11.6)
61 to 80 332 6.08
(3.5 to
8.6)
53.2
(47.8 to
58.6)
12.4
(8.9 to
16.0)
30.7
(25.7 to
35.7)
46.5
(41.1 to
51.9)
61.1 (55.8 to
66.4)
12.1 (8.6 to
15.7)
aDMT1, type 1 diabetes mellitus; DMT2, type 2 diabetes mellitus; GDM, gestational diabetes mellitus; IGT, impaired glucose tolerance; HPN, hypertension; CHD,
coronary heart disease. Data are presented as percentages (95% confidence interval).
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T h el a s to v e r a l lc r u d ep r e v a l e n c eo fD M T 2i nt h eK S A ,
as well as the central region in particular (Riyadh), was
23.7%, with an age-adjusted prevalence of 21.9% [7]. In
the present study, the crude prevalence was 21.3%, with a
calculated age-adjusted prevalence of 31.6%. The slight
decrease in crude prevalence in the current study is neg-
ligible, considering the age range of the previous study,
which was ages 30 to 70 years compared to ages 7 to 80
years in this study. Of note, in the previous report, 3,883
patients from the central region were studied, as opposed
to the 9,149 patients included in this study. Interestingly,
the age-adjusted prevalence of obesity in the central
region was previously 40.0%, the same prevalence
observed in the current study. These findings suggest
that obesity is a major contributor to DMT2, but not the
only one, and, in this instance, cannot explain the
observed rise in the prevalence of the disease in the KSA.
It is apparent that the prevalence of DMT2 in the
region has worsened, and the war against DMT2 in the
kingdom is still far from over. Sadly, our results are
beyond the predicted estimates of Shaw and colleagues
[20], who stated that the biggest increase in the number
of patients with DMT2 will be in developing nations.
Several reasons may account for the higher prevalence
of DMT2 in the KSA. The prevalence of conventional
risk factors for DMT2, such as the full metabolic syn-
drome (MetS) and its individual manifestations, are still
alarming among adult Saudis, 37% of whom have the
full MetS [21], while just recently partial Metabolic syn-
drome (MetS) and isolated MetS manifestations were
documented to be extremely high even among Saudi
children [22]. In both cases, dyslipidemia accounted for
almost 90% of the patient population [21,22].
The emergence of novel risk factors for insulin resis-
tance in this population has also come into play and
includes, but is not limited to, vitamin D deficiency
[23,24], smoking cessation [25] and deficient sleep [26].
Treatment-wise, diabetes carei nt h ep r i m a r yc a r es e t -
ting remains far from desirable [27], and, while limited
Figure 1 Trends in the prevalence of chronic noncommunicable diseases in the Kingdom of Saudi Arabia from 2000 to 2010.( A) Age-
adjusted prevalence of type 2 diabetes mellitus in Saudi Arabia according to gender (1997 [36], 2004 [7], 2011 (present study)). (B) Coronary
artery disease. (C) Hypertension. (D) Obesity. Previous estimates shown are from the central region (Riyadh) and do not include other regions.
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ness of DMT2 in the KSA, one recent study revealed
p o o rk n o w l e d g eo fD M T 2r i s kf a c t o r sa n dp r e v e n t i v e
measures among Saudi patients in the eastern region
[28]. In addition, the general population still has an
extremely high prevalence of physical inactivity, which is
a major risk factor for all the diseases included in the
study, including hypertension [29,30]. Last, granted that
DMT2 and other chronic diseases are polygenic disor-
ders, the high consanguinity marriages among the Saudi
population might be a contributing factor [31]. Any
combination of the above risk factors, as well as an
increase in the exposure to stress, might explain why
the prevalence of chronic diseases in Saudi adults has
increased even in the absence of a change in the preva-
lence of obesity [32].
In our study, there was an apparent gender difference
i nt h ep r e v a l e n c eo fD M T 2 ,w i t ht h ep r e v a l e n c ei nm e n
higher than that in women. Such a difference was docu-
mented in a similar screening program done in the cen-
tral region in the 1990s [33]. While it is known that men
generally have a shorter life expectancy than women, sev-
eral studies have highlighted lifestyle risk factors that are
more frequent among Saudi males, including tobacco
smoking [34], obesity and eating habits [35] and, just
recently, vitamin D deficiency [36]. These factors cumu-
latively, but not completely, explain why there are more
Saudi men than women with DMT2 and other chronic
noncommunicable diseases. Furthermore, perhaps, the
KSA and the Arabian Peninsula in general maintain a
highly patriarchal society, which may place men at higher
levels of chronic psychological stress than women, which
in turn may contribute to metabolic and inflammatory
stress over time, leading to several cell aging mechanisms
and ultimately to chronic noncommunicable diseases
such as DMT2 and CAD [37,38].
With the exception of gestational diabetes mellitus
(GDM) and CAD, the burden of otherwise adult-onset,
chronic, noncommunicable diseases mentioned in this
study is most striking and alarming in the pediatric
cohort. This finding further expands and complicates
the already challenging burden of these diseases. Aside
from the environmental factors already mentioned, we
recently demonstrated, in families from the same cohort,
that multiple metabolic parameters, including circulating
levels of key adipocytokines such as leptin and adipo-
nectin, are significantly transmitted from parents to
their offspring, with this phenomenon manifesting as
early as the preteen years [39]. This finding, com-
pounded by a metabolically adverse gestational and
postnatal environment, which is prevalent in the KSA
[40], adds to the susceptibility of the already genetically
predisposed individual to a lifetime of insulin resistance
and related morbidities.
We acknowledge several limitations of the present
study. The prevalence of CAD was based only on the
number of known cases, so the true prevalence of CAD
in the cohort is expected to be higher. Furthermore,
while current estimates may not necessarily reflect the
true prevalence at a national level, since patients were
recruited only in the central region, the findings are, on
their own, strongly indicative of the need for a more
aggressive approach to battle this epidemic.
Conclusions
In conclusion, this follow-up epidemiologic study shows
that the prevalence of DMT2 in the KSA, specifically in
its central region, has increased by a whopping 10.0% in
just a decade, while it shows no improvement in the age-
adjusted prevalence of obesity and a modest increase in
the prevalence of hypertension and CAD. Translating
these findings to aggressive health policies at the grass-
roots level and strict implementation of diabetes care is
necessary to efficiently restrain the disease. Emerging risk
factors for DMT2 specific to the Saudi population should
also be addressed and further explored.
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